Market Closed -
NSE India S.E.
05:13:51 28/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
85.25
INR
|
-2.35%
|
|
-1.79%
|
-40.63%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,292
|
867.6
|
376.7
|
1,514
|
1,801
|
1,540
|
Enterprise Value (EV)
1 |
1,566
|
1,154
|
649.1
|
1,919
|
2,027
|
1,605
|
P/E ratio
|
-9.36
x
|
-5.86
x
|
-1.1
x
|
-7.82
x
|
-11.1
x
|
-7.37
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.32
x
|
1.58
x
|
0.54
x
|
1.95
x
|
1.98
x
|
2.44
x
|
EV / Revenue
|
2.81
x
|
2.1
x
|
0.93
x
|
2.47
x
|
2.23
x
|
2.54
x
|
EV / EBITDA
|
-17.6
x
|
-21
x
|
-25.2
x
|
219
x
|
-13.9
x
|
-6
x
|
EV / FCF
|
-16
x
|
-54.8
x
|
-5.48
x
|
-20.4
x
|
-4.22
x
|
18.2
x
|
FCF Yield
|
-6.25%
|
-1.82%
|
-18.3%
|
-4.9%
|
-23.7%
|
5.49%
|
Price to Book
|
1.13
x
|
0.83
x
|
0.38
x
|
1.91
x
|
2.86
x
|
2.08
x
|
Nbr of stocks (in thousands)
|
16,186
|
16,186
|
24,703
|
24,703
|
24,703
|
24,703
|
Reference price
2 |
79.85
|
53.60
|
15.25
|
61.30
|
72.90
|
62.35
|
Announcement Date
|
11/08/18
|
30/08/19
|
04/09/20
|
07/09/21
|
06/09/22
|
30/08/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
557.1
|
550.3
|
696.9
|
778.1
|
910.8
|
632
|
EBITDA
1 |
-88.89
|
-55.05
|
-25.76
|
8.783
|
-145.4
|
-267.4
|
EBIT
1 |
-153.3
|
-119.8
|
-89.64
|
-60.03
|
-216
|
-334
|
Operating Margin
|
-27.52%
|
-21.78%
|
-12.86%
|
-7.72%
|
-23.72%
|
-52.85%
|
Earnings before Tax (EBT)
1 |
-175.3
|
-149.5
|
-135.1
|
-89.93
|
-239
|
-383.8
|
Net income
1 |
-138.1
|
-148.1
|
-243.8
|
-193.8
|
-161.9
|
-209
|
Net margin
|
-24.79%
|
-26.9%
|
-34.98%
|
-24.9%
|
-17.77%
|
-33.07%
|
EPS
2 |
-8.534
|
-9.147
|
-13.84
|
-7.843
|
-6.553
|
-8.461
|
Free Cash Flow
1 |
-97.91
|
-21.06
|
-118.5
|
-93.97
|
-480.2
|
88.08
|
FCF margin
|
-17.57%
|
-3.83%
|
-17.01%
|
-12.08%
|
-52.73%
|
13.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/08/18
|
30/08/19
|
04/09/20
|
07/09/21
|
06/09/22
|
30/08/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
273
|
287
|
272
|
405
|
227
|
64.9
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-3.076
x
|
-5.21
x
|
-10.58
x
|
46.11
x
|
-1.558
x
|
-0.2426
x
|
Free Cash Flow
1 |
-97.9
|
-21.1
|
-119
|
-94
|
-480
|
88.1
|
ROE (net income / shareholders' equity)
|
-11.4%
|
-13.5%
|
-23.9%
|
-21.8%
|
-18.1%
|
-29.8%
|
ROA (Net income/ Total Assets)
|
-5.69%
|
-4.4%
|
-3.44%
|
-2.35%
|
-7.54%
|
-13.7%
|
Assets
1 |
2,427
|
3,366
|
7,086
|
8,261
|
2,146
|
1,529
|
Book Value Per Share
2 |
70.70
|
65.00
|
39.80
|
32.00
|
25.50
|
29.90
|
Cash Flow per Share
2 |
0.4000
|
1.540
|
0.1600
|
0.3600
|
1.050
|
0.0100
|
Capex
1 |
57.3
|
8.67
|
25.8
|
56.1
|
276
|
4.68
|
Capex / Sales
|
10.29%
|
1.58%
|
3.71%
|
7.21%
|
30.32%
|
0.74%
|
Announcement Date
|
11/08/18
|
30/08/19
|
04/09/20
|
07/09/21
|
06/09/22
|
30/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -40.63% | 2.76Cr | | +16.31% | 4.23TCr | | +16.32% | 2.13TCr | | +19.36% | 1.53TCr | | +18.71% | 1.44TCr | | +52.78% | 1.28TCr | | -0.05% | 678.76Cr | | -12.24% | 658.31Cr | | -8.87% | 572.55Cr | | +11.64% | 550.82Cr |
Generic Pharmaceuticals
|